Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It provides long‑term reversible contraception and can be used to manage heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirena, a levonorgestrel‑releasing intrauterine system, is indicated for hormonal contraception and treatment of menstrual disorders.

- Contraception: provides up to five years of highly effective, reversible birth control. - Heavy menstrual bleeding (menorrhagia): reduces menstrual blood loss and improves anemia. - Benign endometrial hyperplasia: may be employed to treat non‑cancerous overgrowth of the uterine lining.

Adverse reactions may occur with any intrauterine device. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Cramping or pelvic pain after insertion - Ovarian cyst formation - Breast tenderness - Headache

Serious or Rare Side Effects: - Uterine perforation during insertion - Device expulsion or displacement - Pelvic inflammatory infection - Ectopic pregnancy if conception occurs - Severe allergic reaction (anaphylaxis)

Prior to insertion and during use, certain precautions help ensure safety and effectiveness.

- Pregnancy testing: confirm non‑pregnant status before insertion. - Uterine evaluation: screen for fibroids, congenital anomalies or malignancy. - Infection risk: insert under sterile conditions and monitor for signs of infection. - Bleeding disorders: assess coagulation status and advise on potential increased bleeding. - Smoking: advise cessation in women over 35 years of age. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel may interact with other medicines that affect hormone metabolism or efficacy.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce levonorgestrel levels. - Rifampin: can decrease hormonal effectiveness. - Certain antiretroviral protease inhibitors: potential reduction in contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole, itraconazole): may increase hormone concentrations. - Some antibiotics (e.g., tetracycline, metronidazole): limited evidence, monitor for breakthrough bleeding. - Herbal supplements such as St. John’s wort: may lower levonorgestrel effectiveness.